Navigation Links
Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
Date:5/1/2009

LACHEN, Switzerland, May 1 /PRNewswire/ --

- Company Working With Authorities to Ensure Adequate Supply of Virally Inactivated Plasma Derivatives

The impending influenza pandemic will have implications for global stocks of life-saving blood and blood products, warns Swiss-based global biopharmaceutical company, Octapharma.

But it has reiterated the safety of its plasma derivatives and is working closely with health authorities and plasma suppliers to maintain the safety profile and continuous supply of its lifesaving products.

The threat to blood supplies arises as blood transfusion authorities across the globe remind blood donors to stay away if they have 'flu-like symptoms. In Germany, the Paul Ehrlich Institute, which tests blood products on behalf of the German federal health ministry, has recommended against using blood donated by people who have travelled to countries affected by the swine influenza outbreak or who have been in close contact with people who have 'flu-like symptoms or were in 'flu-affected countries in the previous 14 days.

Octapharma makes plasma derivatives used in a range of medical emergencies. The new swine H1N1 virus, with its epicentre in Mexico, does not endanger the safety of Octapharma's products. Octaplas(R), is a virally inactivated pooled plasma, which can be used in emergency situations whenever plasma transfusion is required.

Currently, Octapharma has sufficient supplies of Octaplas(R) to satisfy usual client demand. Production can be increased by up to 30 percent if demand increases. Octapharma already provides 100 per cent of plasma needs with Octaplas(R) for transfusion in Norway, Finland and Portugal.

During the manufacture of Octaplas(R), the product undergoes a solvent-detergent treatment that destroys the lipid enveloped membrane of a virus, making it inactive and unable to infect.


'/>"/>

SOURCE Octapharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
2. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
3. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) Needle
4. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
5. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
8. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. MultiCell Technologies Signs Liver Stem Cell R&D Agreement To Develop Products for the Study of Liver Cancer
11. Evidence Lacking in Multivitamin Study of Womens Risk of Cancer, Heart Disease or Death, Says Natural Products Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... N.J. , July 22, 2014  Vernalis plc ... achievement of proof-of-concept (POC) for CCP-08, the third ... prescription cough cold collaboration. Under this collaboration, POC ... a successful human pilot comparative study against an ... achieving POC, Vernalis will make a milestone payment ...
(Date:7/22/2014)... 2014 Quantum Materials Corporation (OTCQB:QTMM) (QMC) announced today the addition ... to the Board of Directors. QMC also announced formation of ... QMC Chief Science Officer and Board of Directors Member, along with ... University and Mr. Tomio Gotoh , a pioneer of the ... " Quantum Materials welcomes two new outside Board members, Mr. ...
(Date:7/22/2014)... July 22, 2014 ... company focused on solid dose formulations of therapeutics ... formulation of octreotide acetate achieved successful results in ... currently marketed liquid product (Sandostatin®).  Based on these ... production process to a contract manufacturing organisation (CMO), ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2
... 22, 2011 GeNO LLC ( www.genollc.com ), ... announced commencement of  the PHiano Study: A Phase ... Hypertension in patients with Pulmonary Arterial Hypertension (PAH) ... (PH-IPF) using Inhaled NITROSYL™ nitric oxide (NO).  The ...
... March 22, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ...  J. Michael Pearson, currently Valeant,s Chief Executive Officer (CEO), as ... who remains on the Valeant Board as an independent Board ... role as CEO and has agreed to extend his contract ...
Cached Medicine Technology:GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 2GeNO LLC Initiates Study of Inhaled NITROSYL™ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients 3
(Date:7/23/2014)... 23, 2014 PartnerTech Inc. , ... Lawrenceville, Georgia, welcomed Andreas von Uexkull to their facilities, ... the U.S. von Uexkull, a top trade official from ... of the U.S. to bring awareness and insight to ... Investment Partnership (TTIP). , As an expert on ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Previously, the crew ... pencil and a spreadsheet. Now, the department’s 53 ... Scheduling and Workforce Management system. , “Scheduling our personnel with ... It was hard to keep track of when people could ... this time to this time, and we would have to ...
(Date:7/23/2014)... Controlling pain during childbirth and post delivery may reduce ... a Northwestern Medicine perinatal psychiatrist, in a July 23 ... Wisner,s editorial is based on a new Chinese study ... anesthesia during a vaginal delivery had a much lower ... the epidural. , "Maximizing pain control in labor and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Print ... Print Audit Facilities Manager web portal. Facilities Manager ... releases of the software as well as numerous ... , Print Audit Facilities Manager is a powerful, ... to remotely collect meter reads, automate supplies fulfillment ...
(Date:7/22/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and ... of white party dresses to its product category. ... now available on its website. As a special offer, all ... can get a discounted rate, up to 54% off. , ... customers, so its marketing specialist believes the new white party ...
Breaking Medicine News(10 mins):Health News:Swedish Official Tours PartnerTech’s U.S. Facility 2Health News:Swedish Official Tours PartnerTech’s U.S. Facility 3Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 2Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 3Health News:Controlling childbirth pain tied to lower depression risk 2Health News:Print Audit® Releases Facilities Manager 3.1.0R 2Health News:Elegant White Party Dresses Now Provided by Distinguished Company iFitDress.com 2
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Vertical punch designed to create a 1.5mm clean cylindrical hole. Rotatable for convenient positioning. Flat Handle. Overall length 87mm....
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Medicine Products: